Intuitive Surgical ISRG is preparing to lower customer costs for selected robotic-assisted procedures through its Extended Use Program (“EUP”), reflecting a strategic trade-off between near-term instrumentation and accessories (I&A) revenues and long-term market expansion.
Beginning first-half 2027, the company plans to increase the useful life of a subset of EndoWrist instruments compatible with its fourth- and fifth-generation da Vinci platforms. The initiative targets benign, high-volume procedures where affordability can influence adoption, particularly in cost-sensitive geographies and healthcare systems with lower reimbursement rates.
The strategy could put pressure on I&A revenue per procedure as customers extend the use of eligible instruments before replacing them. In the second quarter of 2026, I&A revenues rose 18% year over year to $1.73 billion, while da Vinci I&A revenue per procedure reached approximately $1,830, compared with $1,800 a year earlier.
Management is yet to quantify EUP’s financial impact, with further details expected following its analysis and pricing decisions. The rollout is expected to have a gradual impact throughout 2027 rather than result in an immediate, one-time change.
However, Intuitive Surgical is prioritizing growth and profitability together, and believes lower procedure costs can unlock incremental demand. By lowering the cost of robotic surgery for selected benign procedures, EUP could encourage hospitals and physicians to increase utilization, particularly in markets where cost has limited adoption. Higher utilization and a broader customer base could strengthen the company’s installed ecosystem and support recurring revenue opportunities over time.
The initiative comes as Intuitive Surgical remains profitable, reporting a 42% adjusted operating margin in the second quarter. Its broader strategy is to use engineering innovation, manufacturing scale and cost reductions to extend access without compromising product quality or reliability. The near-term trade-off impact will likely lead to slower I&A revenue growth per procedure while driving the longer-term opportunity for a larger market share and higher system utilization.
Peer Updates
Stryker SYK is improving operating leverage through tighter spending controls, stronger gross margins and operational execution. In the second quarter of 2026, adjusted gross margin increased 60 basis points year over year to 66%, supported by favorable business mix, cost discipline and a net benefit from tariff-related costs.
Adjusted operating margin expanded 170 basis points to 27.4%. Gross margin improvement was complemented by lower adjusted selling, general and administrative expenses as a percentage of sales. Adjusted EPS rose 17.9% to $3.69, outpacing 9% organic sales growth and demonstrating improved profitability despite ongoing recovery from the cybersecurity incident.
Medtronic MDT is pursuing structural cost reductions through product portfolio simplification, manufacturing efficiencies and supply-chain improvements while continuing to fund growth initiatives. In the first quarter of fiscal 2027, cost-reduction measures contributed 50 basis points to gross margin, net of inflation, while disciplined pricing added another 30 basis points.
The company rationalized more than 9,000 SKUs to streamline operations and improve supply-chain efficiency. Adjusted operating profit increased 15% to $2.3 billion, and operating margin rose 10 basis points to 23.7%, despite unfavorable business mix and higher selling expenses. Management expects operating profit growth of approximately 10% and 50 basis points of margin expansion for fiscal 2027.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).